DOI: http://dx.doi.org/10.18203/2349-2902.isj20185460

Correlation of HER2/neu receptors and other prognostic factors in breast carcinoma

Srihari S., John Amalan A., Sivakumar D., Gobinath M.

Abstract


Background: Breast cancer is the most common malignancy and the leading cause of cancer related death among women all around the world. Evaluation of prognostic factors including biomarkers is highly recommended for the best management and therapeutic decision of breast cancer patients. Aim was to study the correlation of HER2/Neu receptors and other prognostic factors in breast carcinoma.

Methods: Patients who are clinically diagnosed as carcinoma breast a detailed history will be taken. Patients were assigned TNM staging according to AJCC classification and posted for surgery than to find out the receptor status from that specimen.

Results: In 60 cases, there is no significant correlation and association between the prognostic factors (age, menstrual status, tumour size, side of disease, nodal positivity, pathological subtypes, histological grading except ER receptor positivity PR receptor positivity) and HER2neu receptor positivity. Significant association noted between the HER2NEU receptor positivity and ER, PR receptor negativity. ER AND PR receptor status it shows that a significant proportion of PR receptor activation is independent on ER receptor activation. And also this independent PR receptor positive status give false positive results depends upon staining pattern ,transport method of tissue specimen.

Conclusions: Our study results indicate the importance of ER, PR and HER-2/neu expression as prognostic factors for therapeutic decision.


Keywords


Breast carcinoma, Breast prognostic factors, ER, HER-2/neu, PR

Full Text:

PDF

References


Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, et al. Standardisation of HER-2/neu testing: Result of an international proficiency-testing study. Mod Pathol. 2007;20:584-91.

Mascaro A, Farina M, Gigli R, Vitelli CE, Fortunato L. Recent advances in the surgical care of breast cancer patients. World J Surg Oncol. 2010 Dec;8(1):5.

Sondik EJ. Breast cancer trends, incidence, mortality and survival. Cancer. 1994;74:995-9.

Lal P, Tan LK. Correlation of HER-2/neu status with estrogen, progesterone receptor and histological features in 3,655 invasive breast carcinoma. Am J Clin Pathol. 2005;123(4):541-6.

Gown AM. Current issues in estrogen receptor and HER-2/neu testing by immunohistochemical method in breast cancer. Mod Pathol. 2008;21:S8-S15.

Rosen PP, Menendez Botet CJ, Nisselbaum JS, Urban JA, Miké V, Fracchia A, et al. Pathological review of Breast lesions analyzed for Estrogen receptor protein. Cancer Res. 1975;35:3187-94.

Wibur D. Barrows GH. Estrogen, progesterone receptor and HER-2/neu analysis in pure in situ carcinoma-an IHC analysis. Mod. Pathol. 1993;6(2):114-20.

Lici, Darling JR, Malone KE. Incidence of invasive breast cancer by HR status from 1992-1998. J Clin Oncol. 2003;21:28-34.

Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, Chinoy RF. Hormone receptor status of breast cancer in India: a study of 798 tumours. The breast. 2000 Oct 1;9(5):267-70.

Dutta CV, Chopra GS, Sahai K, Nema SK. Hormone receptors, Her-2/Neu and chromosomal aberrations in breast cancer. Med J Armed Forces India. 2011;64(1):11-5.

Mudduwa LK. Quick score of hormone receptor status of breast carcinoma: correlation with the other clinicopathological prognostic parameters. Indian J Pathol Microbiol. 2009;52(2):159-63.

Shet T, Agrawal A, Nadkarni M, Palkar M, Havaldar R, Parmar V, et al. Hormone receptors over the last 8 years in a cancer referral center in India. What was and what is? Indian J Pathol Microbiol. 2009 Apr-Jun;52(2):171-4.

Kumar V, Tewari M, Singh U, Shukla HS. Significance of Her-2/neu protein over expression in Indian breast cancer patients. Indian J Surg. 2008;69(4):122-8.

Reiner A, Reiner G, Spona J, Schemper M, Holzner JH. Histopathologic characterization of human breast cancer in correlation with ER status. A comparison of IHC and biochemical analysis. Cancer. 1988;61:1149-54.

Rosen PP, Lesser ML, Arroya CD, Cranor M, Borgen P, Norton L. IHC detection of HER-2 in patients with axillary lymph node negative breast cancer. A study of epidemiological risk factors and prognosis. Cancer. 1995;75:1320-6.

Soomro S, Shousha S, Taylor P, Shephard HM, Feldmann M. cerb-2 in different histological sub types. J Clin Pathol. 1991;44:211-4

Kunen-Boumeester V, Vanderkwast TH, Van putten WL, Claassen C, van Ooijen B, Henzen-Logmans SC. Immunohistochemistry of Androgen receptor in relation of ER, PR. Int J Cancer. 1992;52:581-4.

Wargotz ES, Norris HJ. Metaplastic carcinoma of breast. Hum Pathol. 1989 Jul;20(7):628-35.

Riva C, Danese E, Caprara C, Rocca PC, Massarelli G, Tot T, et al. Immunohistochemical study of AR in breast carcinoma. evidence of their frequent expression in lobular carcinoma. Virchows Arch. 2005;447:695-700.

Goyle S, Karmarkar S, Ambulkar I, Borker A, Ingle G, Advani SH. Presentation trends of breast cancer patients at a single cancer institute in India. J Clin Oncol. 2008 May 20;26(15_suppl):11571.

Bhargava R, Strieebel J, Beriwal S. Prevalence, morphological features and proliferation indices of breast carcinoma molecular classes using IHC surrogate markers. Int J Clin Pathol. 2009;2(5):444-55.